Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Trial Profile

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Aflibercept (Primary) ; OPT 302 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Opthea
  • Most Recent Events

    • 30 Jan 2019 New source identified and integrated(EudraCT2018-003298-90)
    • 29 Jan 2019 According to an Opthea media release, reporting of primary data analysis from Phase IIa portion is anticipated to occur by the end of 2019.
    • 26 Oct 2018 According to an Opthea media release, results from this trial were presented at the Ophthalmology Innovation Summit (OIS), held in conjunction with the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago on Thursday, October 25th, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top